Publications

Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregório AC, Valério-Fernandes Â, Gomes-da-Silva LC, Rosa MS, Moura V, Ramalho-Santos J, Simões S, Moreira JN.
Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Biomaterials. 69:76-88 (2015). Epub 2015 Aug 6.
Fonseca NA, Gomes-da-Silva LC, Moura V, Simões S, Moreira JN.
Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Journal of Controlled Release. 196:122-131 (2014). Epub 2014 Oct 10.
Fonseca NA, Gregório AC, Valério-Fernandes A, Simões S, Moreira JN.
Bridging cancer biology and the patients’ needs with nanotechnology-based approaches.
Cancer Treatment Reviews. 40(5):626-35 (2014). Epub 2014 Feb 22. Review.
Gomes-da-Silva LC, Santos AO, Bimbo LM, Moura V, Ramalho JS, Pedroso de Lima MC, Simões S, Moreira JN.
Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
International Journal of Pharmaceutics. 434(1-2):9-19 (2012). Epub 2012 May 19.
Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN.
Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Accounts of Chemical Research. 45(7):1163-71 (2012). Epub 2012 May 8.
Moura V, Lacerda M, Figueiredo P, Corvo ML, Cruz ME, Soares R, de Lima MC, Simões S, Moreira JN.
Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Breast Cancer Research and Treatment. 133(1):61-73 (2012). (IF: 4.859; Ranking in the category of Oncology: 34; quartile Q1)
Mendonça LS, Moreira JN, de Lima MC, Simões S.
Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.
Biotechnology and Bioengineering. 107(5):884-93 (2010). (IF: 3.700; Ranking in the category of Biotechnology and Applied Microbiology: 34; quartile Q1)
Pinto AC, Moreira JN, Simões S.
Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
Prostate. 71(1):81-90 (2011). (IF: 3.377; Ranking in the category of UROLOGY & NEPHROLOGY: 13; quartile Q1)
Pinto AC, Ângelo S, Moreira JN, Simões S.
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Cancer Chemotherapy and Pharmacology, 67(2):275-284 (2011). (IF: 2.759; Ranking in the category of ONCOLOGY: 84; quartile Q2)
Santos AO, Gomes da Silva LC, Bimbo LM, Pedroso de Lima MC, Simões S, Moreira JN.
Design of peptide-targeted liposomes containing nucleic acids.
Biochimica et Biophysica Acta, 1798(3):433-441 (2010). (IF: 4.647; Ranking in the category of Biochemistry and Molecular Biology: 64; quartile Q1)
Mendonça L, Firmino F, Moreira JN, Pedroso de Lima MC, Simões S.
Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for Chronic Myeloid Leukemia treatment.
Bioconjugate Chemistry, 21(1): 157-168 (2010). (IF: 5.002; Ranking in the category of Biochemistry and Molecular Biology: 56; quartile Q1)
Cardoso A, Trabulo S, Moreira JN, Düzgüneş N, Pedroso de Lima MC.
Targeted lipoplexes for siRNA delivery
Methods in Enzymology, 465:267-287 (2009). (IF: 1.626; Ranking in the category of BIOCHEMISTRY & MOLECULAR BIOLOGY: 213; quartile Q3)
Pinto AC, Moreira JN, Simões S.
Ciprofloxacin sensitizes a hormone-refractory prostate cancer cell line to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Cancer Chemotherapy and Pharmacology, 64(3):445-454 (2009). (IF: 2.759; Ranking in the category of ONCOLOGY: 84; quartile Q2)
Moreira JN, Santos A, Moura V, Pedroso de Lima MC, Simões S.
Non-viral lipid-based nanoparticles for cancer systemic gene silencing.
Journal of Nanoscience and Nanotechnology, 8(5):2187–2204 (2008). (IF: 1.351; Ranking in the category of MATERIALS SCIENCE, MULTIDISCIPLINARY: 94; quartile Q2)
Fonseca C, Moreira JN, Ciudad CJ, Pedroso de Lima MC, Simões S.
Targeting of sterically stabilized pH-sensitive liposomes to human T-leukemia cells
European Journal of Pharmaceutics and Biopharmaceutics, 59(2):359-366 (2005). (IF: 4.304; Ranking in the category of PHARMACOLOGY & PHARMACY: 37; quartile Q1)
Simões S, Moreira JN, Fonseca C, Nejat Düzgünes N, Pedroso de Lima MC.
On the formulation of pH-sensitive liposomes with long circulation times.
Advanced Drug Delivery Reviews, 56(7):947-965 (2004). (IF: 13.577; Ranking in the category of PHARMACOLOGY & PHARMACY: 4; quartile Q1)
Moreira JN, Ishida T, Gaspar R, Allen TM.
Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity.
Pharmaceutical Research, 19(3):265-269 (2002). (IF: 4.456; Ranking in the category of PHARMACOLOGY & PHARMACY: 33; quartile Q1)
Allen TM, Sapra P, Moase E, Moreira J, Iden D.
Adventures in targeting.
Journal of Liposome Research, 12(1-2):5-12 (2002). (IF: 1.823; Ranking in the category of PHARMACOLOGY & PHARMACY: 152; quartile Q3)
Moreira JN, Gaspar R, Allen TM.
Targeting Stealth liposomes in a murine model of human small cell lung cancer.
Biochimica et Biophysica Acta, 1515(2):167-176 (2001). (IF: 4.647; Ranking in the category of Biochemistry and Molecular Biology: 64; quartile Q1)
Moreira JN, Hansen CB, Gaspar R, Allen TM.
A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer.
Biochimica et Biophysica Acta, 1514(2):303-317 (2001). (IF: 4.647; Ranking in the category of Biochemistry and Molecular Biology: 64; quartile Q1)
Slepushkin VA, Simões S, Dazin P, Newman MS, Guo LS, Pedroso de Lima MC, Düzgüneş N.
Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo.
Journal of Biological Chemistry, 272(4):2382-2388 (1997). (IF: 5.328; Ranking in the category of Biochemistry and Molecular Biology: 50; quartile Q1)